Navigation Links
Novel technique to produce stem cells from peripheral blood
Date:11/1/2012

Stem cells are a valuable resource for medical and biological research, but are difficult to study due to ethical and societal barriers. However, genetically manipulated cells from adults may provide a path to study stem cells that avoid any ethical concerns. A new video-protocol in JoVE (Journal of Visualized Experiments), details steps to generate human induced pluripotent stem cells (iPSC) from cells in the peripheral blood. The technique has been developed by Boston University's Dr. Gustavo Mostoslavsky and his colleagues.

Stem cells are unique because they can self-renew, differentiate into multiple cell types (pluripotency), and are immortal. Fertilized eggs produce embryonic stem cells with the potential to differentiate into any other cell type. Despite their value, embryonic stem cells pose a variety of ethical, legal and political implications that cause scientists to look for less controversial paths of study. "As opposed to human embryonic stem cells that originate in fertilized eggs, human induced pluripotent stem cells can be generated from any cell, and there are no ethical barriers to this," Dr. Mostoslavsky explains.

"Our article describes a methodology to obtain high quality, induced pluripotent stem cell lines," Dr. Mostoslavsky continues. His work is particularly interesting to the stem cell research community because "blood is an easily accessible sample for most laboratories. Our procedure uses a vector we created and produced a few years ago, and is very efficient. Our colleagues are very interested in that high efficiency. We published in JoVE because there are some technical details in the protocol that are best conveyed with a video-protocol. "

Dr. Mostoslavsky uses induced pluripotent stem cells to model genetic lung diseases, providing a fast track to study rare diseases in the laboratory. This technique will prove a valuable time and cost saving resource for other scientists interested in genetic disorders. The video-protocol was published in JoVE on October 31, 2012. JoVE Senior Science Editor Dr. Nandita Singh tells us, "We are excited to describe the generating of human iPSC using a lentiviral vector the Yamanaka factors. This vector was developed in Dr. Mostoslavsky's lab. The ease of obtaining the tissue sample combined with the high efficiency of reprogramming makes this method a very valuable tool in the field. The JoVE format will help the scientific community to accurately replicate this methodology.


'/>"/>

Contact: Neal Moawed
press@jove.com
617-245-0137
The Journal of Visualized Experiments
Source:Eurekalert

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology: